IGM Biosciences Inc.’s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company’s pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower their ratings.
IGM Biosciences’ stock tumbles as analysts weigh in on pivot plan with dismay
RELATED ARTICLES
